Timothy DeVere Cook - 24 Feb 2023 Form 4 Insider Report for Athenex, Inc.

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
24 Feb 2023
Net transactions value
+$499
Form type
4
Filing time
27 Feb 2023, 16:01:19 UTC
Previous filing
13 Feb 2023
Next filing
13 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $499 +182 +8.4% $2.74 2,361 24 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 3,500 24 Feb 2023 Common Stock 3,500 $345.80 Direct F3
holding ATNXQ Stock Option (Right to Buy) 1,500 24 Feb 2023 Common Stock 1,500 $205.20 Direct F3, F4
holding ATNXQ Stock Option (Right to Buy) 450 24 Feb 2023 Common Stock 450 $71.20 Direct F3, F5
holding ATNXQ Restricted Stock Units 338 24 Feb 2023 Common Stock 338 Direct F6, F7, F8
holding ATNXQ Stock Option (Right to Buy) 3,750 24 Feb 2023 Common Stock 3,750 $13.31 Direct F3, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
F3 This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
F4 This option vests in four equal annual installments beginning on August 27, 2021.
F5 This option vests in four equal annual installments beginning on September 16, 2022.
F6 Each restricted stock unit represents a contingent right to receive one share of stock.
F7 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F8 The restricted stock units were adjusted to reflect the reverse stock split that occurred on February 15, 2023.
F9 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs